Tudor Investment Corp
CASC

Tudor Investment Corp’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Tudor Investment Corp’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-8,127
Closed -$80K – 1744
2016
Q3 		$80K Hold
8,127
– – ﹤0.01% 1355
2016
Q2 		$46K Hold
8,127
– – ﹤0.01% 1554
2016
Q1 		$62K Hold
8,127
– – ﹤0.01% 1643
2015
Q4 		$108K Buy
8,127
+784
+11% +$13.5K ﹤0.01% 1527
2015
Q3 		$121K Sell
7,343
-3,200
-30% -$65.6K ﹤0.01% 1412
2015
Q2 		$237K Buy
10,543
+6,717
+176% +$106K 0.01% 1252
2015
Q1 		$37K Hold
3,826
– – ﹤0.01% 1410
2014
Q4 		$44K Hold
3,826
– – ﹤0.01% 1401
2014
Q3 		$44K Sell
3,826
-1,417
-27% -$21.6K ﹤0.01% 1308
2014
Q2 		$102K Buy
5,243
+117
+2% +$2.06K ﹤0.01% 1100
2014
Q1 		$92K Sell
5,126
-1,524
-23% -$25K ﹤0.01% 1130
2013
Q4 		$70K Buy
+6,650
New +$74.3K ﹤0.01% 1221

Other funds holding CASC

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SH
Sandia Holdings Greenwich, Connecticut $213M AUM 29.35% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

Tudor Investment Corp's CASC Position: Q4 2016 in Review

Tudor Investment Corp sold out of Cascadian Therapeutics, Inc. (CASC) in Q4 2016, closing a stake of 8,127 shares — an estimated $80K sold.

Tudor Investment Corp first reported a position in CASC in Q4 2013 and held it in 12 quarters. The position peaked at $237K in Q2 2015. 57 funds tracked by Wall St. Rank hold CASC as of Q4 2016.

  • Tudor Investment Corp reported no remaining Cascadian Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
  • Tudor Investment Corp sold 8,127 Cascadian Therapeutics, Inc. shares in Q4 2016, an estimated $80K.
  • Tudor Investment Corp first reported a position in Cascadian Therapeutics, Inc. in Q4 2013 and held it in 12 quarters.
  • Tudor Investment Corp's Cascadian Therapeutics, Inc. position peaked at $237K in Q2 2015.
  • 57 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q4 2016.

Based on Tudor Investment Corp's 13F filing for Q4 2016, filed 14 Feb 2017.